<?xml version="1.0" ?>
<TimeML xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://timeml.org/timeMLdocs/TimeML_1.2.1.xsd">

<DOCID>695194695470</DOCID>

<DCT><TIMEX3 tid="t0" type="DATE" value="20170129" temporalFunction="false" functionInDocument="CREATION_TIME">January 29, 2017</TIMEX3></DCT>

<TITLE>HealthCare Royalty Partners Announces New Chief Medical Officer, Senior-Level Promotions, and Further Regional Expansion [India Infoline News Service]</TITLE>


<TEXT>
HealthCare Royalty Partners Announces New Chief Medical Officer, Senior-Level Promotions, and Further Regional Expansion Business Wire India 
 
HealthCare Royalty Partners ("HCR") <EVENT eid="e1" class="REPORTING">announced</EVENT> several firm developments: 
 
New Chief Medical Officer: 
 
As of <TIMEX3 tid="t1" type="DATE" value="2017-01">January 2017</TIMEX3>, Dr. Warren Cooper has <EVENT eid="e2" class="OCCURRENCE">assumed</EVENT> the role of Managing Director and Chief Medical Officer at HCR. Dr. Cooper initially <EVENT eid="e3" class="OCCURRENCE">joined</EVENT> the team in <TIMEX3 tid="t2" type="DATE" value="2016">2016</TIMEX3>, <EVENT eid="e4" class="OCCURRENCE">consulting</EVENT> as an Industry Advisor. Dr. Cooper is a UK-trained physician with over <TIMEX3 tid="t3" type="DURATION" value="P35Y">35 years</TIMEX3> of experience in the global pharmaceutical industry. HCR's senior professionals have <EVENT eid="e5" class="OCCURRENCE">known</EVENT> Dr. Cooper for over <TIMEX3 tid="t4" type="DURATION" value="P1E">a decade</TIMEX3>, <EVENT eid="e6" class="OCCURRENCE">working</EVENT> closely with him when he <EVENT eid="e7" class="OCCURRENCE">served</EVENT> as CEO of Prism Pharmaceuticals ("Prism"), a portfolio company at their prior firm. Prism was a specialty pharmaceutical company that <EVENT eid="e8" class="OCCURRENCE">developed</EVENT> the antiarrhythmic agent NEXTERONE, and was ultimately <EVENT eid="e9" class="OCCURRENCE">acquired</EVENT> by Baxter International in <TIMEX3 tid="t5" type="DATE" value="2011">2011</TIMEX3> for $338 million. Prior to <EVENT eid="e10" class="OCCURRENCE">serving</EVENT> as CEO of Prism, Dr. Cooper <EVENT eid="e11" class="OCCURRENCE">spent</EVENT> <TIMEX3 tid="t6" type="DURATION" value="P12Y">12 years</TIMEX3> with Merck, initially as a UK clinical research physician, then as head of European and subsequently Worldwide Clinical Research Operations. Dr. Cooper also previously <EVENT eid="e12" class="OCCURRENCE">led</EVENT> AstraMerck's (now AstraZeneca PLC) cardiovascular division. HCR looks forward to <EVENT eid="e13" class="OCCURRENCE">drawing</EVENT> on Dr. Cooper's tremendous clinical, regulatory and operational experience as it evaluates new investment opportunities. 
 
Investment Professional Promotions: 
 
HCR has <EVENT eid="e14" class="OCCURRENCE">promoted</EVENT> John Urquhart to a Principal of the firm. Mr. Urquhart was among the first employees at HCR, <EVENT eid="e15" class="OCCURRENCE">joining</EVENT> the firm as an analyst in <TIMEX3 tid="t7" type="DATE" value="2007">2007</TIMEX3> and <EVENT eid="e16" class="OCCURRENCE">re-joining</EVENT> in <TIMEX3 tid="t8" type="DATE" value="2012">2012</TIMEX3> after <EVENT eid="e17" class="OCCURRENCE">receiving</EVENT> his M.B.A. from The Wharton School of the University of Pennsylvania. Mr. Urquhart has over <TIMEX3 tid="t9" type="DURATION" value="P1E">a decade</TIMEX3> of healthcare investing experience in the royalty and structured finance market. 
 
HCR has also <EVENT eid="e18" class="OCCURRENCE">promoted</EVENT> Anthony Rapsomanikis to Vice President. Mr. Rapsomanikis <EVENT eid="e19" class="OCCURRENCE">joined</EVENT> HCR as an Associate in <TIMEX3 tid="t10" type="DATE" value="2012">2012</TIMEX3>, and was <EVENT eid="e20" class="OCCURRENCE">promoted</EVENT> to Director of West Coast Business Development after <EVENT eid="e21" class="OCCURRENCE">establishing</EVENT> the firm's San Francisco office in <TIMEX3 tid="t11" type="DATE" value="2015">2015</TIMEX3>. The San Francisco office <EVENT eid="e22" class="OCCURRENCE">launched</EVENT> HCR's strategic initiative to <EVENT eid="e23" class="OCCURRENCE">regionalize</EVENT> its business development efforts and better <EVENT eid="e24" class="OCCURRENCE">serve</EVENT> the needs of counterparties in key geographic areas. 
 
"John and Tony's promotions are well <EVENT eid="e25" class="OCCURRENCE">deserved</EVENT> and <EVENT eid="e26" class="OCCURRENCE">serve</EVENT> as recognition of their growth and contributions to the firm over <TIMEX3 tid="t12" type="DURATION" value="PXY">the past several years</TIMEX3>," <EVENT eid="e27" class="REPORTING">commented</EVENT> Clarke Futch, co-founder and Chairman of the Investment Committee at HCR. 
 
Regional Office Expansion: 
 
HCR is <EVENT eid="e28" class="I_STATE">pleased</EVENT> to <EVENT eid="e29" class="OCCURRENCE">announce</EVENT> its plans to <EVENT eid="e30" class="OCCURRENCE">open</EVENT> a Boston, MA office in <TIMEX3 tid="t13" type="DATE" value="2017">the first half of 2017</TIMEX3>, which will be <EVENT eid="e31" class="OCCURRENCE">led</EVENT> by John Urquhart. Mr. Urquhart will <EVENT eid="e32" class="OCCURRENCE">work</EVENT> closely with Clarke Futch, Paul Hadden (Managing Director - Business Development) and the rest of the senior investment team, most of whom will <EVENT eid="e33" class="ASPECTUAL">continue</EVENT> to be based in the firm's headquarters in Stamford, CT. 
 
Paul Hadden <EVENT eid="e34" class="REPORTING">commented</EVENT>, "The <EVENT eid="e35" class="OCCURRENCE">opening</EVENT> of our Boston office <EVENT eid="e36" class="OCCURRENCE">follows</EVENT> the success of HCR's San Francisco office <EVENT eid="e37" class="OCCURRENCE">opening</EVENT> in <TIMEX3 tid="t14" type="DATE" value="2015">2015</TIMEX3> and <EVENT eid="e38" class="STATE">furthers</EVENT> our goal of <EVENT eid="e39" class="OCCURRENCE">strengthening</EVENT> local coverage and relationships in the key life science and R D centers. Recent data <EVENT eid="e40" class="REPORTING">shows</EVENT> that Boston and the San Francisco / Bay Area each <EVENT eid="e41" class="OCCURRENCE">garnered</EVENT> about one-third of all biotech venture capital investment in <TIMEX3 tid="t15" type="DATE" value="2016">2016</TIMEX3> and it is important for us to <EVENT eid="e42" class="ASPECTUAL">continue</EVENT> to <EVENT eid="e43" class="OCCURRENCE">focus</EVENT> on these markets." 
 
About HealthCare Royalty Partners 
 
HCR is a private investment firm that purchases royalties and uses debt-like structures to <EVENT eid="e44" class="OCCURRENCE">invest</EVENT> in commercial or near-commercial stage life science assets. HCR has $3.4 billion in cumulative capital commitments and is <EVENT eid="e45" class="OCCURRENCE">headquartered</EVENT> in Stamford, CT. Over <TIMEX3 tid="t16" type="DATE" value="200">the past decade</TIMEX3>, HCR's senior professionals have <EVENT eid="e46" class="OCCURRENCE">completed</EVENT> more than 60 healthcare investments. For more information, visit www.healthcareroyalty.com. 
 
>
</TEXT>


<MAKEINSTANCE eiid="ie44" eventID="e44" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie39" eventID="e39" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie38" eventID="e38" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie19" eventID="e19" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie18" eventID="e18" pos="VERB" tense="PRESENT" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie35" eventID="e35" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie34" eventID="e34" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie33" eventID="e33" pos="VERB" tense="NONE" aspect="NONE" polarity="POS" modality="WOULD" />
<MAKEINSTANCE eiid="ie32" eventID="e32" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie31" eventID="e31" pos="VERB" tense="PAST" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie30" eventID="e30" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie11" eventID="e11" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie10" eventID="e10" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie13" eventID="e13" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie12" eventID="e12" pos="UNKNOWN" tense="PAST" aspect="PERFECTIVE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie15" eventID="e15" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie14" eventID="e14" pos="VERB" tense="PRESENT" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie17" eventID="e17" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie16" eventID="e16" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie42" eventID="e42" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie37" eventID="e37" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie36" eventID="e36" pos="UNKNOWN" tense="PRESENT" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie40" eventID="e40" pos="UNKNOWN" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie43" eventID="e43" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie41" eventID="e41" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie9" eventID="e9" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie8" eventID="e8" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie5" eventID="e5" pos="VERB" tense="PRESENT" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie4" eventID="e4" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie7" eventID="e7" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie6" eventID="e6" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie1" eventID="e1" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie3" eventID="e3" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie2" eventID="e2" pos="VERB" tense="PRESENT" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie24" eventID="e24" pos="UNKNOWN" tense="INFINITIVE" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie25" eventID="e25" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie26" eventID="e26" pos="VERB" tense="FUTURE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie27" eventID="e27" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie20" eventID="e20" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie21" eventID="e21" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie22" eventID="e22" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie23" eventID="e23" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie46" eventID="e46" pos="VERB" tense="PRESENT" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie45" eventID="e45" pos="UNKNOWN" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie28" eventID="e28" pos="ADJECTIVE" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie29" eventID="e29" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />

<TLINK lid="TL1" eventInstanceID="ie11" relatedToTime="t6" relType="IS_INCLUDED" />
<TLINK lid="TL9" timeID="t8" relatedToEventInstance="ie17" relType="BEFORE" />
<TLINK lid="TL5" eventInstanceID="ie27" relatedToTime="t12" relType="IS_INCLUDED" />
<TLINK lid="TL13" timeID="t4" relatedToEventInstance="ie5" relType="INCLUDES" />
<TLINK lid="TL11" timeID="t6" relatedToEventInstance="ie11" relType="INCLUDES" />
<TLINK lid="TL10" timeID="t8" relatedToEventInstance="ie16" relType="INCLUDES" />
<TLINK lid="TL0" eventInstanceID="ie19" relatedToEventInstance="ie20" relType="SIMULTANEOUS" />
<TLINK lid="TL3" eventInstanceID="ie16" relatedToEventInstance="ie17" relType="AFTER" />
<TLINK lid="TL8" timeID="t10" relatedToEventInstance="ie19" relType="INCLUDES" />
<TLINK lid="TL7" timeID="t14" relatedToEventInstance="ie37" relType="INCLUDES" />
<TLINK lid="TL2" eventInstanceID="ie15" relatedToTime="t7" relType="IS_INCLUDED" />
<TLINK lid="TL4" eventInstanceID="ie42" relatedToEventInstance="ie43" relType="AFTER" />
<TLINK lid="TL6" timeID="t2" relatedToEventInstance="ie3" relType="INCLUDES" />
<TLINK lid="TL12" timeID="t7" relatedToEventInstance="ie17" relType="BEFORE" />
</TimeML>
